AIM ImmunoTech shares are trading higher after the company announced that it will present data on its lead drug Ampligen for the treatment of Ebola virus.

Benzinga Newsdesk www.benzinga.com Positive 95.1%

Neg 0% Neu 0% Pos 95.1%

Comments

No comments yet. Be the first!